New expedited service line designed for biotechs with timeline constraints, launched in response to client demandCan accelerate timeline to GMP ...

The SK pharmteco group is now offering a standardized viral vector and plasmid manufacturing process to a global audience. The global approach can help customers move to batches for clinical trials in ...

Advances company’s ambition to provide fully integrated and comprehensive solution for viral vector manufacturing Mirus Bio’s leading GMP transfection reagents complement company’s upstream ...

Oxford, UK – 11 March 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or the “Company"), a leading gene and cell therapy group, is pleased to announce that it has completed its deal with ...

SYDNEY, March 18, 2026 (GLOBE NEWSWIRE) -- Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s first commercial viral vector Contract Development and Manufacturing Organisation (CDMO), ...

Viral vector-based cell therapy uses modified viruses to deliver a healthy gene into a cell to treat a disease. The virus’ shell delivers the gene and the vectors, with the genetic information they ...

-- Viral Vector Facility Further Strengthens Vertical Integration of Kite’s Global CAR T-cell Therapy Manufacturing Network, Supports Growing Demand of Company’s Blood Cancer Treatments -- -- Kite is ...

CBM to provide Asimov's clonal HEK293 viral vector production platform to clients for preclinical and clinical manufacturing Clonal HEK293 suspension cell line is GMP-banked and qualified, ready for ...

Kite Pharma's viral vector plant in Southern California has been cleared for liftoff, and, with that, the Gilead Sciences company is touting its position as the only cell therapy player able to make ...

End-to-end digital twins for continuous automated manufacturing could slash production costs compared to batch manufacturing.